NCT02750215View on ClinicalTrials.gov

A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

May 31, 2021

Study Completion Date

May 31, 2021

Conditions
Malignant Non-small Cell Neoplasm of Lung Stage IV
Interventions
DRUG

Capmatinib (INC280)

treatment with Capmatinib (INC280)

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT02750215 - A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor | Biotech Hunter | Biotech Hunter